RC48 Combined With PD-1 and Radiotherapy as Bladdersparing Therapy in Patients With Muscular Infiltrating Bladder Uroepithelial Carcinoma With Limited HER-2 Expression Following Maximum Electrical Resection or Partial Cystectomy
Latest Information Update: 05 Sep 2023
At a glance
- Drugs Disitamab vedotin (Primary) ; Toripalimab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions
Most Recent Events
- 09 Aug 2023 New trial record